Nurix Therapeutics, Inc

Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.

U.K. regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first half of 2022

Nurix Therapeutics Announces Regulatory Clearance to Initiate Phase 1 Clinical Trial of NX-5948 and Presents New Preclinical Data at the American Society of Hematology Annual Meeting

Nurix Therapeutics is advancing a unique therapeutic approach of targeted protein modulation. The Company's current focus is on cancer treatment and small molecule immuno-oncology agents.

Nurix: Advancing Targeted Protein Modulation Therapies

Food and Drug Administration clears DeTIL-0255 to initiate Phase 1 clinical trial

Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors

DeTIL-0255 is a drug-enhanced investigational new cell therapy product candidate with potentially superior T cell properties compared to conventional TIL

Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference

The clinical-stage biopharmaceutical company posted positive news regarding its lead therapy -- a BTK inhibitor that could fight certain blood-based cancers.

Why Nurix Therapeutics Stock Soared More Than 21% Wednesday

SVB Leerink raised the price target on Nurix Therapeutics Inc (NASDAQ: NRIX) to $64 from $50, with an Outperform rating, seeing an upside of almost 92%. Analyst Christopher Liu notes that Nurix presented preliminary NX-2127 pharmacokinetics/pharmacodynamics data.

Why Did SVB Leerink Beef Up Target Price For Nurix Therapeutics?

Robust BTK target degradation achieved in all patients treated to date

Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies

Presentation to include initial pharmacokinetic and BTK degradation data

Nurix Therapeutics to Present Initial Target Degradation Data from First Phase 1 Trial of NX-2127 in B Cell Malignancies at the 4th Annual Targeted Protein Degradation Summit

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of 1.52% and 17.49%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock?

Nurix Therapeutics, Inc. (NRIX) Reports Q3 Loss, Tops Revenue Estimates

Initiated Phase 1 trial of lead CBL-B E3 ligase inhibitor program NX-1607 in patients with cancer

Nurix Therapeutics Reports Third Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointments of Judith A. Reinsdorf and Paul M. Silva to its board of directors, effective October 1, 2021. Ms. Reinsdorf is the former executive vice president and general counsel of Johnson Controls International, and Mr. Silva is the former senior vice president, chief accounting officer at Vertex Pharmaceuticals Incorporated.

Nurix Therapeutics Expands its Board of Directors with the Addition of Two Industry Leaders

Initiated Phase 1 trial of lead program NX-2127 in patients with relapsed or refractory B-cell malignancies

Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

SAN FRANCISCO, June 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Stefani A. Wolff has joined the company as chief operating officer and executive vice president of product development. Ms. Wolff brings to Nurix over 30 years of leadership experience in oncology and immunology most recently from Principia Biopharma Inc., where she served as chief development officer and formerly senior vice president of strategy and operations overseeing Principia's portfolio including BTK targeted agents. During her tenure at Principia, she successfully guided drug pipeline strategy and led many functions over time, including the company's manufacturing and technical operations, regulatory and quality, clinical operations, project and portfolio management, medical affairs, commercial and communications functions until its acquisition by Sanofi in September, 2020.

Nurix Therapeutics Announces Appointment of Stefani A. Wolff as Chief Operating Officer and Executive Vice President, Product Development

Orally available NX-5948 is a potent selective degrader of Bruton's Tyrosine Kinase (BTK) without IMiD activity

Nurix Therapeutics Announces Presentation of Preclinical Data from NX-5948 Program Demonstrating Significant Reduction of Inflammation in a Model of Autoimmune Disease

SAN FRANCISCO, June 01, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the appointment of Clay Siegall, Ph.D., to its board of directors. Dr. Siegall is a co-founder of Seagen Inc. (formerly Seattle Genetics, Inc.) and serves as its president, chief executive officer, and chairman of the board.

Nurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its Board of Directors

NX-5948, a potent selective degrader of BTK, significantly reduces inflammation in a model of autoimmune disease NX-5948, a potent selective degrader of BTK, significantly reduces inflammation in a model of autoimmune disease

Nurix Therapeutics Announces Upcoming Presentation of NX-5948 Preclinical Data at the EULAR 2021 Virtual Congress

On track to initiate Phase 1 trials for four wholly owned drug candidates in 2021

Nurix Therapeutics Reports First Quarter Fiscal 2021 Financial Results and Provides a Corporate Update

SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix's chief executive officer, will participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14th, 2021 at 11:45 a.m. ET.

Nurix Therapeutics Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

Research focused on targeted degradation of MYCN for the potential treatment of neuroblastoma and medulloblastoma Program is one of four in Alex's Lemonade Stand Foundation-funded $18.5 million Crazy 8 Initiative

Nurix Therapeutics Announces Collaboration for the Discovery of Novel Drugs to Treat Pediatric Cancers

CBL-B inhibitor NX-1607 mediates anti-tumor activity through both T cells and NK cells Preclinical tumor models support clinical development of NX-1607 as monotherapy or in combination with PD-1 blockade

Nurix Therapeutics Announces Presentation of NX-1607 Preclinical Data at AACR

SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the closing of its underwritten public offering of 5,175,000 shares of its common stock at a public offering price of $31.00 per share, which includes 675,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, were $160.4 million.

Nurix Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix's chief executive officer, will participate and present at the following conferences in March:

Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences

SAN FRANCISCO, March 04, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a public offering price of $31.00 per share. The public offering was upsized from the previously announced size of 4,000,000 shares of its common stock. All shares of common stock are being offered by Nurix. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $139.5 million. In addition, Nurix has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on March 9, 2021, subject to the satisfaction of customary closing conditions.

Nurix Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. All of the shares of common stock are being offered by Nurix. In addition, Nurix intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock.

Nurix Therapeutics Announces Launch of Proposed Public Offering of Common Stock

First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies

News for Nurix Therapeutics, Inc Stock (NRIX)